Rhabdomyosarcoma (RMS) is a high-risk pediatric sarcoma that resembles developing skeletal muscle. Transcriptional dysregulation drives RMS pathogenesis in tumors carrying chimeric transcription factors (“fusion-positive (FP)”), and those without (“fusion-negative” (FN)). Here, we develop a novel approach against RMS...
Brian J. Abraham, Annika L. Gustafson, S. Nance et al.· Cancer Research· 0 citations
Most cancer therapeutics that show preclinical promise fail in clinical trials, underscoring the need for complementary disease models. Over the past two decades, zebrafish models have matured from a tool for studying vertebrate development into a versatile platform spanning the translational cancer pipeline. Transgeni...
Gabriel Forn-Cuní, Bruno Lopes-Bastos, D. Langenau et al.· Disease Models & Mechanisms· 0 citations
Fusion-negative Rhabdomyosarcoma (FN-RMS) is a common childhood soft tissue sarcoma with hundreds of cases diagnosed annually in the United States. Despite having good treatment outcomes in the primary tumor setting, metastatic RMS has an abysmal prognosis with less than 20% of patients surviving the disease. Thus, t...
Jihee Lee, M. Bakr, D. Kannambadi et al.· Cancer Research· 0 citations
Fusion-negative rhabdomyosarcoma (FN-RMS) is a childhood muscle cancer where relapse and refractory disease lead to poor outcomes. Our group has recently shown that FN-RMS is a cancer stem cell (CSC) disease and that these CD44+/CD90+/EGFR+ cells likely contribute to therapy-resistance, yet the precise mechanisms gov...
S. Mathavarajah, Tiffany C. Y. Eng, Elisa J. Quantin et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
